Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension

Day²,

et al. 2004

Eye

Purpose To compare ocular tolerability of dorzolamide 2%, brinzolamide 1%, and placebo given three times daily. Methods A prospective, double-masked, three-centre, crossover comparison in which 25 ocular hypertensive or primary-open angle glaucoma subjects were randomized to receive dorzolamide, brinzolamide, or placebo three times daily for 3 days. Intraocular pressure, visual acuity, a visual analogue scale, and ocular and systemic symptom queries were completed at the end of each period.

Section: Discussionmentioning

confidence: 90%

“…15,16 In the regulatory trial by Silver and associates, 15 when brinzolamide was used as monotherapy, there were statistically fewer nonsolicited complaints of ocular stinging upon instillation compared to dorzolamide monotherapy. Any stinging in this study was characterized as mild with both topical carbonic anhydrase inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

Day²,

et al. 2004

Eye

“…22 Brinzolamide provides statistically significant IOP reductions from baseline that are clinically relevant in the majority of patients with elevated IOP. 23 Brinzolamide is formulated at physiologic pH as an aqueous suspension and has been shown to produce less ocular discomfort (burning and stinging) on instillation than dorzolamide. 23,24 There are conflicting results about the IOP-lowering efficacy of latanoprost after phacoemulsification.…”

Section: Discussionmentioning

confidence: 99%

“…23 Brinzolamide is formulated at physiologic pH as an aqueous suspension and has been shown to produce less ocular discomfort (burning and stinging) on instillation than dorzolamide. 23,24 There are conflicting results about the IOP-lowering efficacy of latanoprost after phacoemulsification. 4,10,12 In the study of Rainer et al, 4 the increase in IOP after phacoemulsification at 6 and 20À24 postoperative hours were 2.2 and 0.3 mmHg, the latter being not statistically different from placebo.…”

Section: Discussionmentioning

confidence: 99%

Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification

Ermiş

Öztürk

İnan

2004

Eye

Purpose To evaluate the intraocular pressure (IOP) lowering effect of travoprost and brinzolamide within the first 24 h after phacoemulsification cataract surgery. Methods This prospective, randomized, double-masked, controlled study comprised 90 eyes of 90 consecutive patients with senile cataract who had uneventful phacoemulsification surgery. Eyes in the first group received travoprost 0.0015%, second group received brinzolamide 1%. Eyes in the third group received balanced salt solution and were used as control. One drop was instilled immediately after surgery. IOP was measured 24 h preoperatively, 6 and 24 h postoperatively. Analysis of variance, Student's-t and w 2 -tests were used for statistical analyses. Results Preoperatively IOP was not significantly different among the three groups (P ¼ 0.653). At 6 and 24 h postoperatively IOP was lower in both travoprost and brinzolamide group when compared to control group (P ¼ 0.018 and 0.015 at 6 h, P ¼ 0.010 and 0.012 at 24 h, respectively). The difference between travoprost and brinzolamide group was not significant (P ¼ 0.859 at 6 h and P ¼ 0.581 at 24 h). Both travoprost and brinzolamide significantly reduced IOP increases when compared to control eyes at 6 and 24 h (P ¼ 0.036 and 0.029 at 6 h, P ¼ 0.010 and 0.007 at 24 h, respectively). The difference in IOP increase at 6 and 24 h between travoprost and brinzolamide group was not significant (P ¼ 0.744 at 6 h and P ¼ 0.672 at 24 h). Conclusion Both travoprost and brinzolamide significantly lowered IOP after small incision phacoemulsification cataract surgery within the first 24 h without any side effect.

“…6,7 For this purpose, significant advances in the development of topical glaucoma medications have been achieved. [8][9][10] In recent years, prostaglandin analogs have gained popularity as first-line drugs for monotherapy; latanoprost for example effectively reduces IOP by increasing aqueous flow through the uveoscleral pathway. [11][12][13][14] …”

Section: Introductionmentioning

confidence: 99%

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost

Nakamura

Nakamura³

et al. 2009

OPTH

Purpose:To investigate the efficacy of dorzolamide 1% (bid or tid) or brinzolamide 1% bid on 24-hour intraocular pressure (IOP) control as well as patients' preference for either drug when added in combination with latanoprost against glaucoma (IOP, 18 mmHg). Methods: In this randomized crossover study patients were assigned to receive latanoprost plus either dorzolamide or brinzolamide for four weeks. Thereafter, patients underwent 24-hour IOP monitoring while continuing to receive dorzolamide (for two successive days/nights: at first bid then tid) or brinzolamide bid (once overnight). They were then switched over to receive the other test medication for a further four weeks and subsequently reexamined for 24-hour IOP. A questionnaire survey on treatment satisfaction was performed. Results: In 20 patients dorzolamide bid or tid or brinzolamide bid exerted significant (p  0.001) reductions of IOP from baseline at all time-points over 24 hours; no difference was detected among the treatment regimens. Significantly (p  0.05) more patients preferred dorzolamide (n = 9) over brinzolamide (n = 2), whereas nine patients gave a neutral answer. Conclusion: Dorzolamide bid or tid and brinzolamide bid when combined with latanoprost therapy elicited significant IOP reduction for 24 hours. It is rational to consider patients' preference of therapeutic regimen especially long-term users such as those with glaucoma.